Immunomodulator agent-related lymphoproliferative disorders

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1532-1540

  Hasserjian, Robert P ^a   Chen, Steve ^b   Perkins, Sherrie L ^c   De Leval, Laurence ^d   Kinney, Marsha C ^e   Barry, Todd S ^b   Said, Jonathan ^f   Lim, Megan S ^g   Finn, William G ^g   Medeiros, L Jeffrey ^h   Harris, Nancy L ^a   O'Malley, Dennis P ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Clarient Inc   (United States)

^c ARUP LABORATORIES   (United States)

^d CHU SART TILMAN   (Belgium)

^e Mays Cancer Center at UT Health San Antonio   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunotherapy; Lymphoma; Monoclonal antibody

Indexed keywords

ADALIMUMAB; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IATROGENIC DISEASE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; T CELL LYMPHOMA; VASCULITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; BELGIUM; FEMALE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IATROGENIC DISEASE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 71149115072     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.131     Document Type: Article

References (26)

1. Pucino Jr F, Harbus PT, Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: where are we going? Am J Health Syst Pharm 2006;63:S19-S41.
2. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204.
3. Van Lent PL, Van De Loo FA, Holthuysen AE, et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995;22:2250-2258.
4. Park SH, Kim CG, Kim JY, et al. Spontaneous regression of EBV-associated diffuse lymphoprolifera-tive disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 2008;28:475-477.
5. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. J Dermatol 2006;213:204-214.
6. Askling J, Baecklund E, Granath F, et al. Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-653.
7. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68:1136-1145.
8. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
9. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-1321.
10. Gaulard P SS, Harris NL, Jaffe ES, et al. Other iatrogenic immunodeficiency-associated lymphoproli-ferative disordersd. In: Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (ed). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Vol., 4th edn. IARC: Lyon, 2008; 350-351.
11. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lym-phoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-2317.
12. Sprouse JT, Werling R, Hanke D, et al. T-cell clonality determination using polymerase chain reaction (PCR) amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled PCR products. Am J Clin Pathol 2000;113:838-850.
13. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961-969.
14. Podolsky DK, Gonzalez G, Hasserjian RP. Case 8-2006: A 71-year-old woman with Crohn's disease and altered mental status. N Engl J Med 2006;354:1178-1184.
15. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46: 3151-3158.
16. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-622.
17. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317: 180-181.
18. Baecklund E, Sundstrom C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-1550.
19. Kamel OW, Holly EA, van de Rijn M, et al. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676-1680.
20. Kamel OW, Weiss LM, van de Rijn M, et al. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996;20:1279-1287.
21. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn' s disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-1030.
22. Hurley MY, George MN, Leonardi CL, et al. A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists. Diagn Pathol 2008;3:13.
23. Deng A, Harvey V, Sina B, et al. Interstitial granulo-matous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Derm 2006;142: 198-202.
24. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNF-alpha blockade. J Am Acad Dermatol 2004;51:660-662.
25. Moseley AC, Lindsley HB, Skikne BS, et al. Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease. J Rheumtol 2000;27: 810-813.
26. Anolik JH, Ravikumar R, Barnard J, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008;180:688-692.